Trials / Completed
CompletedNCT01039805
Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance
A Double-blind, Randomized, Placebo Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in Critically Ill Male and Female Patients With Enteral Feed Intolerance
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The aims of MOT112571 are to assess the pharmacodynamic effects, safety, tolerability, pharmacokinetics, and potential therapeutic benefit of single doses of GSK962040 in critically ill patients with delayed gastric emptying and who are intolerant to enteral feeding.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK962040 (50 mg) | Cohort 1 = 50 mg |
| DRUG | Placebo | matching placebo |
| DRUG | GSK962040 (75 mg) | Cohort 2 = 75 mg |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2009-12-25
- Last updated
- 2017-01-30
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT01039805. Inclusion in this directory is not an endorsement.